The U.S. Food and Drug Administration has granted accelerated approval to YUVIWEL (navepegritide), marking the first once-weekly therapeutic option for pediatric achondroplasia. Developed by Ascendis Pharma, the treatment is indicated for children aged 2 years and older with the rare genetic disorder characterized by abnormal bone growth. The approval establishes a new dosing paradigm for the condition, as existing therapies require more frequent administration schedules.
The regulatory decision was supported by efficacy data from three randomized clinical trials demonstrating improved annualized growth velocity compared to control groups. YUVIWEL delivers continuous systemic exposure to C-type natriuretic peptide (CNP) over a seven-day interval, a mechanism designed to stimulate bone growth in patients with achondroplasia. The accelerated approval pathway reflects the FDA's recognition of the drug's potential to address an unmet medical need in a patient population with limited therapeutic alternatives.
Ascendis Pharma anticipates commercial availability of YUVIWEL in early second-quarter 2026, pending manufacturing and distribution preparations. The approval expands treatment options for families managing achondroplasia and represents a significant milestone for the company's pipeline development.